FR4892M - - Google Patents

Info

Publication number
FR4892M
FR4892M FR40558A FR40558A FR4892M FR 4892 M FR4892 M FR 4892M FR 40558 A FR40558 A FR 40558A FR 40558 A FR40558 A FR 40558A FR 4892 M FR4892 M FR 4892M
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR40558A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Application granted granted Critical
Publication of FR4892M publication Critical patent/FR4892M/fr
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR40558A 1964-09-04 1965-12-02 Expired FR4892M (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1156164A CH415963A (de) 1964-09-04 1964-09-04 Masse zur Herstellung von Tabletten mit protrahierter Wirkung

Publications (1)

Publication Number Publication Date
FR4892M true FR4892M (fr) 1967-03-06

Family

ID=4374676

Family Applications (1)

Application Number Title Priority Date Filing Date
FR40558A Expired FR4892M (fr) 1964-09-04 1965-12-02

Country Status (7)

Country Link
US (1) US3459850A (fr)
AT (1) AT264715B (fr)
BR (1) BR6572781D0 (fr)
CH (1) CH415963A (fr)
DE (1) DE1492253A1 (fr)
FR (1) FR4892M (fr)
GB (1) GB1112332A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549371A1 (fr) * 1983-07-20 1985-01-25 Sanofi Sa Nouvelle composition pharmaceutique contenant de l'acide valproique ou un de ses sels

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1456365A (en) * 1972-10-06 1976-11-24 Gist Brocades Nv Controlled release composition
FI63335B (fi) * 1979-02-02 1983-02-28 Orion Yhtymae Oy Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4461759A (en) * 1983-01-03 1984-07-24 Verex Laboratories, Inc. Constant release rate solid oral dosage formulations of veropamil
JPH0816066B2 (ja) * 1986-07-18 1996-02-21 エーザイ株式会社 持続性薬効製剤
WO1989002742A1 (fr) * 1987-10-05 1989-04-06 Pharmagyn, Inc. Comprime utilise dans le traitement de carences en progesterone
DE19600324A1 (de) 1996-01-08 1997-07-10 Basf Ag Granulate für kosmetische und pharmazeutische Zubereitungen
WO2002045695A2 (fr) 2000-12-05 2002-06-13 Alexander Macgregor Systeme de distribution hydrostatique regulee d'un agent
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP1812025B1 (fr) 2004-11-02 2012-09-05 Chr. Hansen A/S Formulation a bacteriophages stabilisees
KR20200110317A (ko) 2017-12-05 2020-09-23 선오비온 파마슈티컬스 인코포레이티드 결정형 및 이의 제조 방법
BR112020011189A2 (pt) 2017-12-05 2020-11-17 Sunovion Pharmaceuticals Inc. misturas não racêmicas e usos das mesmas
CA3142355A1 (fr) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Formulations a liberation modifiee et utilisations associees
US20240226038A9 (en) * 2022-10-19 2024-07-11 Genexa Inc. Solid pharmaceutical tablet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
US2875130A (en) * 1956-11-20 1959-02-24 Smith Kline French Lab Method of preparing sustained release particles and the product of the method
GB906422A (en) * 1958-05-02 1962-09-19 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical preparations
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
NL128902C (fr) * 1960-06-06
US3346449A (en) * 1963-09-27 1967-10-10 Hoffmann La Roche d-methorphan compositions and methods of making same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2549371A1 (fr) * 1983-07-20 1985-01-25 Sanofi Sa Nouvelle composition pharmaceutique contenant de l'acide valproique ou un de ses sels

Also Published As

Publication number Publication date
US3459850A (en) 1969-08-05
AT264715B (de) 1968-09-10
CH415963A (de) 1966-06-30
DE1492253A1 (de) 1969-12-18
BR6572781D0 (pt) 1973-08-02
GB1112332A (en) 1968-05-01

Similar Documents

Publication Publication Date Title
FR4892M (fr)
AU442366B2 (fr)
BE642652A (fr)
BE632875A (fr)
BE626083A (fr)
BE661229A (fr)
BE623398A (fr)
BE661023A (fr)
BE622126A (fr)
BE660941A (fr)
BE660687A (fr)
BE660649A (fr)
BE660258A (fr)
BE660016A (fr)
BE659915A (fr)
BE659865A (fr)
BE659472A (fr)
BE621510A (fr)
BE613833A (fr)
BE610935A (fr)
BE603534A (fr)
BE659308A (fr)
BE584699A (fr)
BE642588A (fr)
BE659127A (fr)